Corlieve Therapeutics SAS Closes Seed Financing to Develop Therapies for Severe Neurological Conditions

PARIS, Nov. 2, 2020 /PRNewswire/ -- Corlieve Therapeutics today announced the closing of its seed financing led by Kurma Partners and IDinvest Partners, together with Pureos Bioventures. Corlieve is focused on developing novel therapeutics for severe neurological disorders. Corlieve's...

from PR Newswire: https://ift.tt/3mJLQSi